A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
| Status: | Completed |
|---|---|
| Conditions: | Ovarian Cancer, Cancer, Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2018 |
| Start Date: | February 2007 |
| End Date: | January 2012 |
A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
The primary objective is to determine whether LY573636-sodium (hereafter referred to as
LY573636) is effective in treating platinum-resistant ovarian cancer. Patients will receive
an intravenous infusion of study drug once every 28 days. Computed tomography (CT) scans and
CA-125 tests will be done before the first dose and then after every other treatment.
LY573636) is effective in treating platinum-resistant ovarian cancer. Patients will receive
an intravenous infusion of study drug once every 28 days. Computed tomography (CT) scans and
CA-125 tests will be done before the first dose and then after every other treatment.
Inclusion Criteria:
- Diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal
cancer
- At least 18 years old
- Have received at least one but no more than 2 systemic treatment regimens containing
platinum (does not include regimens received before surgery for this cancer)
- Have platinum-resistant disease
Exclusion Criteria:
- Have received more than 2 systemic treatment regimens for platinum-resistant disease
- Serious pre-existing medical conditions
- Actively receiving warfarin (Coumadin) for treatment of venous thrombosis or other
prothrombotic conditions
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials